JP2007509116A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509116A5
JP2007509116A5 JP2006536167A JP2006536167A JP2007509116A5 JP 2007509116 A5 JP2007509116 A5 JP 2007509116A5 JP 2006536167 A JP2006536167 A JP 2006536167A JP 2006536167 A JP2006536167 A JP 2006536167A JP 2007509116 A5 JP2007509116 A5 JP 2007509116A5
Authority
JP
Japan
Prior art keywords
methyl
nitro
phenylamino
trifluoromethyl
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006536167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509116A (ja
Filing date
Publication date
Priority claimed from GBGB0324551.1A external-priority patent/GB0324551D0/en
Application filed filed Critical
Publication of JP2007509116A publication Critical patent/JP2007509116A/ja
Publication of JP2007509116A5 publication Critical patent/JP2007509116A5/ja
Pending legal-status Critical Current

Links

JP2006536167A 2003-10-21 2004-10-21 アンドロゲン受容体モジュレーター Pending JP2007509116A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324551.1A GB0324551D0 (en) 2003-10-21 2003-10-21 Novel compounds
PCT/GB2004/004464 WO2005042464A1 (en) 2003-10-21 2004-10-21 Androgen receptor modulators

Publications (2)

Publication Number Publication Date
JP2007509116A JP2007509116A (ja) 2007-04-12
JP2007509116A5 true JP2007509116A5 (enExample) 2007-12-06

Family

ID=29595536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536167A Pending JP2007509116A (ja) 2003-10-21 2004-10-21 アンドロゲン受容体モジュレーター

Country Status (7)

Country Link
US (1) US20080058383A1 (enExample)
EP (1) EP1685090A1 (enExample)
JP (1) JP2007509116A (enExample)
AU (1) AU2004285744A1 (enExample)
CA (1) CA2543345A1 (enExample)
GB (1) GB0324551D0 (enExample)
WO (1) WO2005042464A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005214167B2 (en) 2004-02-13 2008-08-07 Warner-Lambert Company Llc Androgen receptor modulators
JP2007532621A (ja) 2004-04-13 2007-11-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンモジュレータ
EP1740533A1 (en) 2004-04-22 2007-01-10 Warner-Lambert Company LLC Androgen modulators
MXPA06013115A (es) * 2004-05-11 2007-02-28 Pfizer Prod Inc Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica.
WO2006006065A1 (en) 2004-07-08 2006-01-19 Warner-Lambert Company Llc Androgen modulators
WO2006044707A1 (en) * 2004-10-13 2006-04-27 Smithkline Beecham Corporation Chemical compounds
US7585877B2 (en) 2005-01-10 2009-09-08 Acadia Pharmaceuticals, Inc. Aminophenyl derivatives as selective androgen receptor modulators
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
EP2051935B1 (en) 2006-07-26 2016-09-07 STMicroelectronics Srl Use of nitroaniline derivatives for the production of nitric oxide
BRPI0907844B8 (pt) 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
KR20110044216A (ko) 2008-07-02 2011-04-28 브리티쉬 콜롬비아 캔써 에이전시 브랜치 디글리시드 에테르 유도체 치료법 및 이의 사용 방법
EP2367794B1 (en) 2008-11-24 2013-01-09 Basf Se Curable composition comprising a thermolatent base
KR20100067046A (ko) * 2008-12-10 2010-06-18 동화약품주식회사 신규한 ２，６―위치에 치환된 ３―니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
CN102405043B (zh) 2009-01-09 2017-08-22 得克萨斯州大学系统董事会 前神经原性化合物
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
FR2954316B1 (fr) 2009-12-23 2014-01-03 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954315B1 (fr) * 2009-12-23 2012-02-24 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954317B1 (fr) * 2009-12-23 2012-01-27 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
CA2786319C (en) 2010-01-06 2019-03-12 British Columbia Cancer Agency Branch Bisphenol derivatives and their use as androgen receptor activity modulators
US8987319B2 (en) 2010-02-04 2015-03-24 Radius Health, Inc. Selective androgen receptor modulators
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
JP2013531801A (ja) * 2010-07-02 2013-08-08 ヴェンタナ メディカル システムズ， インク． 標的検出のためのハプテンコンジュゲート
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
CA2804161A1 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2012047617A1 (en) 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
US9701676B2 (en) 2012-08-24 2017-07-11 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9375496B2 (en) 2013-09-09 2016-06-28 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
PL3122426T3 (pl) 2014-03-28 2023-05-15 Duke University Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
BR112017013382A2 (pt) 2014-12-23 2018-02-14 Gilead Sciences Inc método para preparar um composto, composto, e, ácido.
HUE057962T2 (hu) 2015-01-13 2022-06-28 British Columbia Cancer Agency Branch Heterociklusos vegyületek rák képalkotására és kezelésére és eljárás ezek alkalamzására
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
WO2016176665A1 (en) 2015-04-29 2016-11-03 Radius Health, Inc. Methods of treating cancer
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
SMT202200199T1 (it) 2016-06-22 2022-07-21 Ellipses Pharma Ltd Metodi di trattamento del cancro del seno ar+.
EP4374925A3 (en) 2017-01-05 2025-01-15 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
CN110770210A (zh) 2017-05-18 2020-02-07 Pi工业有限公司 新颖的脒化合物
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
CN112423844B (zh) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
US20200123117A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
CN119390714A (zh) 2019-02-12 2025-02-07 雷迪厄斯制药公司 方法和化合物
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN115916170A (zh) 2020-04-17 2023-04-04 埃萨制药股份有限公司 固体形式的n-末端结构域雄激素受体抑制剂及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970423A (en) * 1971-10-04 1976-07-20 Clairol Incorporated Oxidative hair dye compositions
CA1012553A (en) 1972-06-23 1977-06-21 Hirotoshi Nakanishi Process for the production of aromatic diamines
JPS4920129A (enExample) * 1972-06-23 1974-02-22
US4723986A (en) 1986-05-19 1988-02-09 Stauffer Chemical Company Herbicidal oxazolidines and methods of use
JP2701090B2 (ja) * 1990-11-30 1998-01-21 和光純薬工業株式会社 被酸化性呈色試薬
JPH0580375A (ja) * 1991-09-20 1993-04-02 Japan Synthetic Rubber Co Ltd 有機非線形光学素子
JPH0920129A (ja) * 1995-07-05 1997-01-21 Suzuki Motor Corp 車両用暖房装置
DE19612506A1 (de) 1996-03-29 1997-10-02 Wella Ag Oxidationshaarfärbemittel mit einem Gehalt an 2,5-Diaminobenzonitrilen sowie neue 2,5-Diaminobenzonitrile
US6093732A (en) * 1997-12-22 2000-07-25 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
US20020193389A1 (en) * 1998-11-20 2002-12-19 Rifat Pamukeu Method of inhibiting neoplastic cells with imidazoquinazoline derivatives
US6472415B1 (en) * 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
MXPA03001632A (es) * 2000-08-24 2004-09-10 Univ Tennessee Res Corp Moduladores receptores de androgeno selectivos y metodos para usar los mismos.
CN100506801C (zh) * 2000-09-06 2009-07-01 诺华疫苗和诊断公司 糖元合成酶激酶3的抑制剂
DE60236322D1 (de) * 2001-12-07 2010-06-17 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
DE10163251A1 (de) * 2001-12-21 2003-07-03 Henkel Kgaa Neue Entwicklerkomponenten

Similar Documents

Publication Publication Date Title
JP2007509116A5 (enExample)
EP2516398B1 (fr) Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
RU2632875C2 (ru) Способы получения (s)-1-(3-этокси-4-метоксифенил)-2- метансульфонилэтиламина
JP2015526487A5 (enExample)
CZ20032727A3 (cs) Derivát karboxylové kyseliny a jeho sůl
JP2010090128A (ja) 結晶質の化合物ビス［（ｅ）−７−［４−（４−フルオロフェニル）−６−イソプロピル−２−［メチル（メチルスルホニル）アミノ］ピリミジン−５−イル］（３ｒ，５ｓ）−３，５−ジヒドロキシ−６−ヘプテン酸］カルシウム塩
EP1731506A1 (en) 5-hydroxyindole-3-carboxylates derivatives and their use
AU2013277423B2 (en) Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
JP7443414B2 (ja) アンドロゲン受容体のｎ末端ドメインの阻害剤
CS242881B2 (en) Method of 1,4-dihydropyridine's new derivatives production
SK13752002A3 (sk) Difenyléterové zlúčeniny užitočné pri liečení
JPWO2020132014A5 (enExample)
CZ334998A3 (cs) Substituované benzylaminy a farmaceutický prostředek
CN1192728A (zh) 苯基烷烃酰胺衍生物及农业或园艺杀菌剂
SK285037B6 (sk) Spôsob výroby 2-aryl-3-aryl-5-halogénpyridínov
TWI284127B (en) Cyclization process for substituted benzothiazole derivatives
CN1197864C (zh) 吡唑并哒嗪衍生物的制备方法
CN1317265C (zh) 氰基丙烯酸酯衍生物及制备方法和生物活性
CN1533378A (zh) 制备喹唑啉的方法
CN107848968B (zh) 从乙醛酸制备内酰胺的方法
CN1633411A (zh) 用于调节细胞增生的化合物
TWI884201B (zh) 用於製備3-溴-1-(3-氯吡啶-2-基)-1h-吡唑-5-羧酸乙酯的方法
AU2010303243A1 (en) Processes for the preparation of 2-(1-phenylethyl) isoindolin-1-one compounds
CN1166650C (zh) 1,2,3-噻二唑类化合物及其制备方法和生物活性
FR2954316A1 (fr) Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique